Skip to Content

ZTlido Approval History

FDA Approved: Yes (First approved February 28, 2018)
Brand name: ZTlido
Generic name: lidocaine
Dosage form: Patch
Previous Name: Ztilido
Company: Scilex Pharmaceuticals, Inc.
Treatment for: Postherpetic Neuralgia

ZTlido (lidocaine topical system 1.8%) is a transdermal anesthetic formulation for the treatment of pain associated with postherpetic neuralgia.

Development History and FDA Approval Process for ZTlido

DateArticle
Feb 28, 2018Approval Sorrento Therapeutics Subsidiary, Scilex, Receives FDA Approval for Non-Opioid ZTlido (lidocaine topical system) 1.8% for Post-Herpetic Neuralgia Pain
Sep 12, 2017FDA Acknowledges Receipt of Sorrento Therapeutics Inc, NDA for ZTlido
Aug 29, 2017Sorrento Therapeutics, Inc. Submits NDA For ZTlido Next-Generation Lidocaine Patch
Sep 16, 2015FDA Accepts Scilex Pharmaceuticals' NDA Filing for ZTlido
May 15, 2014Scilex Pharmaceuticals Initiates Pivotal Pharmacokinetic Study for Ztilido
Mar 24, 2014Scilex Pharmaceuticals Announces Filing of Investigational New Drug Application for Ztilido

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide